While several chemokine receptors and ligands have been implicated in inflammatory disorders, mounting evidence has highlighted the relevance of CCR1 and CCR5 and their primary ligands (CCL3 and CCL5 for CCR1; CCL3, CCL4, and CCL5 for CCR5) in RA and MS. This evidence concerns the gene CCR5 and myeloid sarcoma.